Ten year period | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Mean | Missing Data Mean, Range | P-value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The annual number of patients | |||||||||||||
BioRheuma patients, N | 4909 | 7256 | 7993 | 7278 | 8023 | 9057 | 9176 | 9225 | 9102 | 9335 | |||
b/tsDMARDs users, N (%) | 1936 (39) | 2855 (39) | 3136 (39) | 3060 (42) | 3419 (43) | 3688 (41) | 3770 (41) | 3869 (42) | 3869 (43) | 4154 (45) | 41% | ||
Demographics | |||||||||||||
Age (years) | 60 (13) | 60 (14) | 59 (14) | 59 (14) | 59 (14) | 59 (14) | 59 (14) | 59 (14) | 60 (14) | 60 (14) | 59.3 | 1.1%, 0–11% | 0.044 |
Female | 74% | 73% | 72% | 72% | 73% | 73% | 73% | 73% | 73% | 72% | 73% | 1.1%, 0–11% | 0.938 |
BMI (kg/m2) | 26 (4.9) | 26 (4.6) | 26 (4.6) | 26 (4.6) | 26 (4.6) | 26 (4.7) | 26 (4.8) | 26 (4.8) | 26 (4.6) | 26 (4.9) | 26 | 9.9%, 2–57% | < 0.001 |
Education (years) | 13 (3.6) | 12 (3.8) | 12 (3.7) | 12 (3.7) | 12 (3.7) | 12 (3.7) | 12 (3.7) | 13 (3.7) | 13 (3.7) | 13 (3.7) | 12 | 9.3%, 1–55% | < 0.001 |
Current Smokers | 23% | 22% | 20% | 19% | 18% | 17% | 16% | 15% | 14% | 14% | 18% | 8.2%, 1–50% | < 0.001 |
Disease Duration (years) | 13 (10) | 13 (11) | 14 (11) | 14 (11) | 14 (11) | 14 (11) | 15 (11) | 14 (11) | 15 (11) | 15 (11) | 14 | 0.0%, 0–0% | < 0.001 |
Enabled Workers | 63% | 59% | 59% | 60% | 57% | 58% | 59% | 59% | 59% | 59% | 59% | 7.4%, 1–45% | 0.393 |
Biomarkers | |||||||||||||
CCP Positive | 82% | 82% | 81% | 81% | 80% | 80% | 81% | 81% | 81% | 81% | 81% | 27%, 14–42% | 0.900 |
RF Positive | 75% | 75% | 74% | 73% | 73% | 73% | 72% | 73% | 73% | 72% | 73% | 45%, 29–61% | 0.798 |
Disease Activity | |||||||||||||
ESR (mm/h) | 19 (16) [14 (17)] | 18 (16) [13 (16)] | 16 (15) [12 (15)] | 16 (14) [12 (14)] | 15 (15) [11 (14)] | 15 (15) [11 (14)] | 14 (14) [10 (13)] | 14 (14) [9 (13)] | 14 (15) [9 (13)] | 14 (15) [9 (12)] | 16 | 26%, 20–32% | < 0.001 |
CRP (mg/L) | 8.4 (17) [4 (7)] | 7.8 (14) [4 (7)] | 6.6 (12) [3 (5)] | 6.2 (10) [3 (5)] | 6.2 (11) [3 (5)] | 6.4 (13) [3 (6)] | 6.4 (17) [3 (4)] | 5.7 (11) [2 (4)] | 5.9 (11) [2 (4)] | 6.0 (11) [2 (4)] | 6.6 | 19%, 15–27% | < 0.001 |
TJC28 (0–28) | 3.4 (4.7) [2 (5)] | 3.1 (4.5) [1 (4)] | 2.7 (4.4) [1 (3)] | 2.5 (4.1) [1 (3)] | 2.4 (3.9) [1 (3)] | 2.1 (3.7) [1 (3)] | 2.1 (3.7) [1 (2)] | 1.9 (3.7) [0 (2)] | 1.9 (3.6) [0 (2)] | 1.7 (3.4) [0 (2)] | 2.4 | 15%, 9–19% | < 0.001 |
SJC28 (0–28) | 2.3 (3.4) [1 (3)] | 2.0 (3.1) [1 (3)] | 1.9 (3.1) [1 (2)] | 1.5 (2.6) [0 (2)] | 1.2 (2.3) [0 (2)] | 1.1 (2.2) [0 (1)] | 1.1 (2.1) [0 (1)] | 1.1 (2.2) [0 (1)] | 0.9 (2.0) [0 (1)] | 0.8 (2.0) [0 (1)] | 1.4 | 15%, 9–19% | < 0.001 |
IGA (VAS, 0–100 mm) | 18 (16) | 18 (16) | 17 (16) | 16 (15) | 16 (15) | 15 (15) | 14 (15) | 14 (15) | 13 (15) | 12 (14) | 15.2 | 40%, 35–50% | < 0.001 |
DAS28(4)-CRP | 3.1 (1.2) | 3.0 (1.2) | 2.8 (1.2) | 2.7 (1.1) | 2.6 (1.1) | 2.6 (1.1) | 2.6 (1.1) | 2.5 (1.1) | 2.5 (1.1) | 2.4 (1.1) | 2.7 | 30%, 26–34% | < 0.001 |
DAS28 Remission | 42% | 46% | 51% | 56% | 57% | 59% | 60% | 63% | 64% | 67% | 56% | 30%, 26–34% | < 0.001 |
DAS28 LDA | 18% | 17% | 17% | 17% | 16% | 16% | 16% | 15% | 16% | 14% | 16% | 30%, 26–34% | 0.034 |
Patient-Reported Outcome Measures | |||||||||||||
PGA (VAS, 0–100 mm) | 33 (24) | 33 (25) | 33 (25) | 32 (25) | 32 (25) | 33 (25) | 33 (25) | 32 (26) | 32 (26) | 32 (26) | 33 | 10%, 8–11% | 0.270 |
Pain (VAS, 0–100 mm) | 32 (25) | 34 (25) | 33 (24) | 32 (25) | 32 (25) | 33 (25) | 32 (25) | 32 (26) | 32 (25) | 32 (26) | 33 | 20%, 14–53% | 0.204 |
MHAQ (0–3) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 (0.5) | 0.5 | 15%, 10–37% | 0.001 |
Fatigue (VAS, 0–100 mm) | 38 (29) | 37 (29) | 38 (29) | 37 (29) | 38 (30) | 39 (30) | 39 (30) | 39 (30) | 40 (310) | 40 (31) | 39 | 37%, 15–54% | 0.006 |
Morning Stiffness (hr) | 0.9 (1.2) | 0.9 (1.3) | 0.9 (1.2) | 0.9 (1.2) | 0.8 (1.2) | 0.9 (1.2) | 0.9 (1.3) | 0.9 (1.2) | 0.9 (1.2) | 0.9 (1.2) | 0.9 | 42%, 16–59% | 0.614 |